Literature DB >> 6538251

Induction of differentiation in HL60 leukaemic cells: a cell cycle dependent all-or-none event.

A W Boyd, D Metcalf.   

Abstract

The human leukaemia cell line (HL60) shows a limited capacity to differentiate spontaneously, but this property can be greatly enhanced by chemical inducers. Sodium butyrate induced differentiation in virtually 100% of HL60 cells over a four-day interval to cells with multiple phenotypic markers of monocytes. Clonogenic analysis in agar demonstrated that differentiated cells (either spontaneous or induced) irreversibly lost clonogenic potential. This appeared to be an all-or-none process with unaffected cells exhibiting unaltered clonogeneity. A study of the kinetics of colony formation showed that most, if not all, cells completed one division in the presence of butyrate and sometimes several divisions before loss of proliferative potential. Despite the uniform spectrum of cell cycle states present in HL60 cultures when butyrate was added, all differentiated cells were shown to be arrested in G1. Evidence was obtained suggesting that the 'switch' into the differentiation pathway occurred during a restricted stage of the cell cycle, either late in the cycle (G2-M) or early in G1.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538251     DOI: 10.1016/0145-2126(84)90029-8

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  14 in total

1.  Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells.

Authors:  S Romero-Steiner; D Libutti; L B Pais; J Dykes; P Anderson; J C Whitin; H L Keyserling; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

Review 2.  Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies.

Authors:  R A Fleck; S Romero-Steiner; M H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

3.  Fluoroquinolone transport by human monocytes: characterization and comparison to other cells of myeloid lineage.

Authors:  S J Bounds; R Nakkula; J D Walters
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  Human fibroblast commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent.

Authors:  V V Ogryzko; T H Hirai; V R Russanova; D A Barbie; B H Howard
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

5.  Identification and characterization of nuclear retinoic acid-binding activity in human myeloblastic leukemia HL-60 cells.

Authors:  C Nervi; J F Grippo; M I Sherman; M D George; A M Jetten
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

6.  Butyric acid: inhibition of non-leukemic and chronic myeloid leukemia granulocyte macrophage clonal growth.

Authors:  E Januszewicz; E Rabizadah; A Novogrodsky; M Shaklai
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

7.  Transcriptional arrest within the first exon is a fast control mechanism in c-myc gene expression.

Authors:  D Eick; G W Bornkamm
Journal:  Nucleic Acids Res       Date:  1986-11-11       Impact factor: 16.971

8.  Regulation of the mRNA for monocyte-derived neutrophil-activating peptide in differentiating HL60 promyelocytes.

Authors:  J Kowalski; D T Denhardt
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

9.  Differences in expression of transcription factor AP-1 in human promyelocytic HL-60 cells during differentiation towards macrophages versus granulocytes.

Authors:  F Mollinedo; C Gajate; A Tugores; I Flores; J R Naranjo
Journal:  Biochem J       Date:  1993-08-15       Impact factor: 3.857

10.  Molecular recognition of acute myeloid leukemia using aptamers.

Authors:  K Sefah; Z W Tang; D H Shangguan; H Chen; D Lopez-Colon; Y Li; P Parekh; J Martin; L Meng; J A Phillips; Y M Kim; W H Tan
Journal:  Leukemia       Date:  2009-01-08       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.